ACC

Acarix appoints Aamir Mahmood as new CEO

Retrieved on: 
Thursday, February 1, 2024
Multimedia, Growth, Lead, American College, Food, Veterans' affairs, Patient, YPO, FDA, Boston Scientific, Marketing, MBA, Cardiology, LivaNova, CRM, AGM, MicroPort, ACC, Organization, Management

STOCKHOLM, Feb. 1, 2024 /PRNewswire/ -- The Board of Acarix AB (publ) announces the immediate appointment of Aamir Mahmood as its new CEO, effective February 1.

Key Points: 
  • STOCKHOLM, Feb. 1, 2024 /PRNewswire/ -- The Board of Acarix AB (publ) announces the immediate appointment of Aamir Mahmood as its new CEO, effective February 1.
  • Mr. Mahmood succeeds Acting CEO Fred Colen and previous CEO Helen Ljungdahl Round.
  • "It is with great pleasure that the Board of Acarix announces the appointment of Aamir Mahmood as the new CEO to lead this exciting phase of rapid growth, especially in the US.
  • Aamir succeeds Helen Ljungdahl Round who was appointed CEO of Acarix in January of 2022.

L2+ Hands-off Assisted Driving Report 2024, with Profiles of Key Players APTIV, BMW, Bosch, Continental, Ford, GM, Mobileye, Nissan, NVIDIA, Qualcomm, Toyota & ZF

Retrieved on: 
Thursday, February 1, 2024
Level 2, L2, Ecosystem, Level 3, LKA, ADAS, SAE, Original equipment manufacturer, Automation, ACC, Security printing

DUBLIN, Feb. 1, 2024 /PRNewswire/ -- The "Growth Opportunities in L2+ Hands-off Assisted Driving" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 1, 2024 /PRNewswire/ -- The "Growth Opportunities in L2+ Hands-off Assisted Driving" report has been added to ResearchAndMarkets.com's offering.
  • However, most OEMs equate L2+ with hands-off assisted driving, where the driver must monitor the driving activity and be available to take over the dynamic driving task when necessary.
  • Higher adoption of L2+ hands-off driving will introduce and drive acceptance of automated driving technologies among consumers.
  • Now, competitive intensity has compelled traditional OEMs to introduce ADAS features by offering hands-off driving in their L2+ vehicles.

Spectra7 and Teledyne LeCroy to Demonstrate Robust Performance Testing of 800Gbps Active Copper Interconnects at DesignCon 2024

Retrieved on: 
Wednesday, January 31, 2024
SAN, Digital signal processing, DSP, Architecture, Exhibition, Teledyne Technologies, The Company, Wire, AOCS, Xena, ACC, Digital signal, Conference

SAN JOSE, Calif., Jan. 31, 2024 /PRNewswire/ -- (TSXV:SEV) (OTCQB:SPVNF) Spectra7 Microsystems Inc. ("Spectra7" or the "Company"), a leading provider of high-performance analog semiconductor products for broadband connectivity markets, and Teledyne LeCroy, a leading provider of electronic design, test and software solutions, announced they will demonstrate their latest 800Gbps product offerings at this year's annual DesignCon Conference Exhibition in Santa Clara, California from Jan 31-Feb 1, 2024. The companies plan to demonstrate robust performance and testing of 800Gbps Active Copper Cable (ACC) products for hyperscale data center applications.

Key Points: 
  • The companies plan to demonstrate robust performance and testing of 800Gbps Active Copper Cable (ACC) products for hyperscale data center applications.
  • The demo will highlight Spectra7's ACCs successfully interoperating with the Teledyne LeCroy's Xena Z800 800GE QSFP-DD800 Test System at 800Gbps speeds.
  • "Spectra7 has created a compelling solution to address the dramatically increasing power and cost of data center interconnects."
  • "Teledyne LeCroy is a global leader in the test and measurement solutions market," said Spectra7 CEO Raouf Halim.

Volta Energy Solutions, world's first manufacturer of copper foil for batteries, to expand business presence in North American EV market

Retrieved on: 
Wednesday, January 31, 2024
Copper, GM, Growth, VES, Vacuum, History, AI, Research, USD, TotalEnergies, Hyundai Motor Company, EV, Bev, Mercedes-Benz, CFL, Polychlorinated biphenyl, ACC, Mitsui, Lithium

Korea's leading companies are entering the North American EV market to build a battery supply chain.

Key Points: 
  • Korea's leading companies are entering the North American EV market to build a battery supply chain.
  • SEOUL, South Korea, Jan. 31, 2024 /PRNewswire/ -- Volta Energy Solutions (VES), developer of the world's first electrodeposited copper foil for batteries, is now penetrating the North America market.
  • VES has started to build a new battery copper foil plant in Quebec, Canada, this year to fill the battery copper foil vacuum in the North American electric vehicle (EV) supply chain.
  • In 2020, the company successfully initiated the mass production of copper battery foil at its Hungary plant, the only battery copper foil manufacturer in Europe.

HeartFlow Announces New Reimbursement Code and Increased Payment for FFRCT

Retrieved on: 
Tuesday, January 23, 2024
American Medical Association, Artificial intelligence, Patient, Research, Hospital, American College of Radiology, Health, Society, Coronary artery disease, ACC, CPT, CMS, Atherosclerosis, ACR, SCCT, CAD, Category, Diagnosis, American College, Physician

The new code, designated by The American Medical Association (AMA), supports FFRCT as the standard of care in assessing patients with suspected coronary artery disease (CAD).

Key Points: 
  • The new code, designated by The American Medical Association (AMA), supports FFRCT as the standard of care in assessing patients with suspected coronary artery disease (CAD).
  • In the hospital setting, CMS increased payment for the FFRCT service by ~7% for 2024.
  • As part of converting to a Category I code, relative value units (RVUs) have been assigned to FFRCT, which provides payment to physicians for the service.
  • “This recognition emphasizes the value and importance of FFRCT Analysis to help clinicians accurately diagnose CAD in patients.

Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck

Retrieved on: 
Thursday, January 18, 2024
Hope, OBT, Neoplasm, Patient, Radiation therapy, MD, ADC, Neck, PD-1, Radiation, Head, NSCLC, ACC, Doctor of Philosophy, Antigen, Ovarian cancer, Lausanne University Hospital, Lung, CPI, CD205, Pharmaceutical industry

OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.

Key Points: 
  • OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.
  • The CD205 receptor is highly overexpressed in solid and liquid tumors with high unmet need, including gastric, lung and ovarian cancer.
  • We look forward to demonstrating the potential value of OBT076, with the hope to provide meaningful benefit for ACC patients.
  • Trial arms are investigating OBT076 both as a monotherapy and in combination with a CPI in these tumors.

Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

Retrieved on: 
Wednesday, January 24, 2024
Cardiology, Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Medical Devices, Software, Artificial Intelligence, Genetics, Nuclear medicine, Entrepreneurship, Artificial intelligence, Patient, Internal medicine, Research, American College of Physicians, MD, Cardio, Emory University, JACC, Innovation, University, Algorithm, Journal of Clinical Investigation, FACC, ACP, ACC, Journal, NIH, Cardiovascular disease, Bachelor of Science, Hospital, Society for Vascular Surgery, Mount Sinai School, American College, Growth, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.
  • The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company’s continued growth and market expansion.
  • “I am excited to join Cardio Diagnostics and contribute to the company’s mission of improving cardiovascular health,” said Dr. Ramjee.
  • Dr. Ramjee will also work to raise awareness of Cardio Diagnostics’ innovative technologies and their potential to improve patient care.

HiRain to Mass Produce First Mobileye EyeQ™6-Based ADAS System in China

Retrieved on: 
Monday, January 22, 2024
Semiconductor, Automotive, General Automotive, Automotive Manufacturing, Technology, Manufacturing, Cloud, OEM, Lite, Multimedia, Partnership, EyeQ, Algorithm, ADAS, ACC, Safety, Transport, AEB, TJA

HiRain Technologies, a system provider of intelligent driving solutions to automakers in China, proudly announces the upcoming production of the Mobileye EyeQ™6 Lite based ADAS system, poised to debut in China in the second quarter of 2024.

Key Points: 
  • HiRain Technologies, a system provider of intelligent driving solutions to automakers in China, proudly announces the upcoming production of the Mobileye EyeQ™6 Lite based ADAS system, poised to debut in China in the second quarter of 2024.
  • The EyeQ6 Lite also supports Cloud-Enhanced ADAS, providing automakers with a single solution for both the Chinese and international markets.
  • "Our collaboration with Mobileye since 2012 has now brought forth the EyeQ6 Lite-based ADAS, HiRain's 7th generation in this series,” said Dr. Chengjian Fan, Deputy General Manager of HiRain.
  • "The EyeQ6 Lite project is a symbol of our steadfast dedication to safety and automotive-grade excellence," stated Elie Luskin, Mobileye Vice President, and Managing Director of Mobileye China.

Spectra7 and Keysight Successfully Achieve Robust Performance Testing of 800Gbps Active Copper Interconnects and Plan Demonstration at DesignCon 2024

Retrieved on: 
Wednesday, January 24, 2024
Exhibition, DSP, SAN, Digital signal, ACC, AOCS, Conference, Ethernet, Wire, Digital signal processing, The Company

SAN JOSE, Calif., Jan. 24, 2024 /PRNewswire/ -- (TSXV:SEV) (OTCQB:SPVNF) Spectra7 Microsystems Inc. ("Spectra7" or the "Company"), a leading provider of high-performance analog semiconductor products for broadband connectivity markets, and Keysight, a leading provider of electronic design, test, security, and software solutions, announced they successfully achieved robust performance testing and will demonstrate their latest 800Gbps product offerings at this year's annual DesignCon Conference Exhibition in Santa Clara, California from Jan 31-Feb 1, 2024. The companies plan to demonstrate robust performance and testing of 800Gbps Active Copper Cable (ACC) products for hyperscale data center applications.

Key Points: 
  • The companies plan to demonstrate robust performance and testing of 800Gbps Active Copper Cable (ACC) products for hyperscale data center applications.
  • In the testing, Spectra7's ACCs successfully interoperated with the Keysight AresONE-M 800GE QSFP-DD800 Layer 1-3 Test System at 800Gbps speeds.
  • Link training produced a very robust low bit error rate (BER) of 3.3e-9 which demonstrates a wide margin over standard required BER.
  • "Their validation of robust performance of our GaugeChangerTM technology in 800Gbps interconnects is a significant milestone in the coming volume deployment of our data center product line."

Digital Medicine Society Convenes Industry Leaders to Streamline Path to Commercial Success for Digital Health Product Developers

Retrieved on: 
Tuesday, January 23, 2024
Roche, Digital health, Patient, ZS Associates, CTA, Dime, Consumer Technology Association, DHPS, Collection, Food and Drug Administration, ZS, University, Engagement, DHP, Digital, IEP, ACHP, Connected health, Investment, ACC, Evaluation, Risk, FDA, Evidence, Organization, Pharmaceutical industry

BOSTON, Jan. 23, 2024 /PRNewswire/ -- Today, the Digital Medicine Society (DiMe) announced it's partnering with Peterson Health Technology Institute (PHTI), ZS Associates, and other leading industry organizations to define how Integrated Evidence Plans (IEP) can be developed, optimized, and used to support the regulatory and commercial success of digital health products (DHPs) on an accelerated timeline. The goal is to streamline the pathways to successful commercialization of high-value, evidence-based DHPs, addressing the top priority reported by industry leaders in DiMe's recent Digital Health Industry Regulatory Needs Assessment: to align best practices between regulatory requirements and decision-making with downstream payers and purchasers.

Key Points: 
  • In today's rapidly evolving and maturing business landscape, addressing the challenges that arise from a lack of evidence for DHPs is crucial.
  • This latest project from DiMe will address these obstacles to help streamline the path to broad adoption of evidence-based digital health technologies, build confidence with digital health purchasing organizations, and optimize health outcomes for the greatest number of patients – all while advancing innovation in the digital health landscape.
  • "Developers have been very successful at securing FDA acceptance and market access opportunities for their digital health products (DHPs).
  • This work builds on DiMe's successful U.S. Digital Health Regulatory Pathways for DHPs and Evidence DEFINED framework to advance the use of IEPs for developing DHPs.